242 related articles for article (PubMed ID: 35721162)
1. Interactions Between Natural Products and Tamoxifen in Breast Cancer: A Comprehensive Literature Review.
Yen C; Zhao F; Yu Z; Zhu X; Li CG
Front Pharmacol; 2022; 13():847113. PubMed ID: 35721162
[No Abstract] [Full Text] [Related]
2. Real-world Chinese herbal medicine for Parkinson's disease: a hospital-based retrospective analysis of electronic medical records.
Lyu S; Zhang CS; Mao Z; Guo X; Li Z; Luo X; Sun J; Su Q
Front Aging Neurosci; 2024; 16():1362948. PubMed ID: 38756536
[TBL] [Abstract][Full Text] [Related]
3. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
[TBL] [Abstract][Full Text] [Related]
4. Hesperidin, piperine and bee venom synergistically potentiate the anticancer effect of tamoxifen against breast cancer cells.
Khamis AAA; Ali EMM; El-Moneim MAA; Abd-Alhaseeb MM; El-Magd MA; Salim EI
Biomed Pharmacother; 2018 Sep; 105():1335-1343. PubMed ID: 30021371
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
6. Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model.
De Oliveira Andrade F; Yu W; Zhang X; Carney E; Hu R; Clarke R; FitzGerald K; Hilakivi-Clarke L
Endocr Relat Cancer; 2019 Mar; 26(3):339-353. PubMed ID: 30640711
[TBL] [Abstract][Full Text] [Related]
7. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
Mai Z; Blackburn GL; Zhou JR
Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
9. In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen.
Chen JL; Chang CJ; Wang JY; Wen CS; Tseng LM; Chang WC; Noomhorm N; Liu HJ; Chen WS; Chiu JH; Shyr YM
Integr Cancer Ther; 2014 May; 13(3):226-39. PubMed ID: 24525674
[TBL] [Abstract][Full Text] [Related]
10. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab.
Chen JL; Wang JY; Tsai YF; Lin YH; Tseng LM; Chang WC; King KL; Chen WS; Chiu JH; Shyr YM
Menopause; 2013 Jun; 20(6):646-54. PubMed ID: 23340260
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of tamoxifen related to estrogen receptor level.
Rose C; Thorpe SM; Løber J; Daenfeldt JL; Palshof T; Mouridsen HT
Recent Results Cancer Res; 1980; 71():134-41. PubMed ID: 6988911
[TBL] [Abstract][Full Text] [Related]
13. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of tamoxifen alone versus tamoxifen in combination wtih gestagen and oestrogen in advanced breast cancer.
Mouridsen HT; Palshof T; Rose C
Recent Results Cancer Res; 1980; 71():169-77. PubMed ID: 6988913
[TBL] [Abstract][Full Text] [Related]
15. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
[TBL] [Abstract][Full Text] [Related]
16. Difluoromethylornithine in combination with tamoxifen in female rats: 13-week oral toxicity study.
Brown AP; Morrissey RL; Crowell JA; Levine BS
Cancer Chemother Pharmacol; 1999; 44(6):475-83. PubMed ID: 10550568
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of UFT plus Tamoxifen for Estrogen-Receptor-Positive Breast Cancer and Tamoxifen plus UFT for Estrogen-Receptor-Negative Breast Cancer : Adjuvant Therapy after Administration of Mitomycin.
Ogita M; Uchino J; Asaishi K; Kubo Y; Tanabe T; Hata A; Hirata K; Mito M;
Clin Drug Investig; 2003; 23(11):689-99. PubMed ID: 17536882
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
19. Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice.
Mai Z; Blackburn GL; Zhou JR
Carcinogenesis; 2007 Jun; 28(6):1217-23. PubMed ID: 17234721
[TBL] [Abstract][Full Text] [Related]
20. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.
Jordan VC; Fritz NF; Tormey DC
Cancer Res; 1987 Jan; 47(2):624-30. PubMed ID: 3098415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
